IL-17A weakens the antitumor immuity by inhibiting apoptosis of MDSCs in Lewis lung carcinoma bearing mice
Metrics: PDF 946 views | HTML 1374 views | ?
Juan Wang1,2,4,*, Yue Zhang1,*, Kai Yin3,*, Peiqi Xu2, Jie Tian2, Jie Ma2, Xinyu Tian2, Yungang Wang2, Xinyi Tang2, Huaxi Xu2, Shengjun Wang1,2
1Department of Laboratory Medicine, The Affiliated People’s Hospital, Jiangsu University, Zhenjiang, China
2Institute of Laboratory Medicine, Jiangsu Key Laboratory of Laboratory Medicine, School of Medicine, Jiangsu University, Zhenjiang, China
3Department of General Surgery, The Affiliated Hospital, Jiangsu University, Zhenjiang, China
4Department of Laboratory Medicine, Changzhou TCM Hospital, Changzhou, China
*These authors contributed equally to this work
Shengjun Wang, email: firstname.lastname@example.org
Jie Tian, email: email@example.com
Keywords: myeloid-derived suppressor cells, interleukin-17, apoptosis, tumor immunology
Received: October 04, 2016 Accepted: December 07, 2016 Published: December 16, 2016
Myeloid-derived suppressor cells (MDSCs) weaken the antitumor immune response through the inhibition of effector T cell activity and the production of immunosuppressive factors in pathological sites. It is well established that interleukin-17A (IL-17A) has a remarkable role on the promotion of inflammation and tumor formation, and IL-17 has been implicated in the enhancement of immunosuppression of MDSCs, which consequently promotes tumor progression. A detailed study of this relationship remains elusive. In our study, we not only confirmed the promotion of IL-17 on Lewis lung carcinoma (LLC) development but also surprisingly showed that IL-17 could extend the fate and enhance the immunosuppressive effect of MDSCs through activating ERK1/2. Additionally, the effect of IL-17 on MDSCs was reversed, even in tumors by blocking ERK1/2. Interdicting the signaling molecule ERK1/2 could increase the apoptosis of MDSCs and weaken the suppressive activity of MDSCs, so that thereafter, the antitumor immunity could be restored partly. Therefore, these findings offer new insights into the importance of IL-17 and the downstream signaling factor ERK1/2 for MDSCs.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.